🌍·2h agoIndustry
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Publisher
V
Vivani Medical
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Vivani Medical
- Region
- 最新
- Scope
- Industry
- Published
- June 25, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investors.vivani.com
Leave the platform to read the original full article on the publisher site.
Source: Vivani Medical
Scope: Industry
Related coverage
More related coverage
Tiziana Life Sciences/3h ago
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Avacta Group/8h ago
Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference
Avacta Group/8h ago
Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer
Merck & Co. (MSD) News/3h ago